|
Laurence Jay Korn, Ph.D., co-founded Protein Design Labs in 1986. He served as Chief Executive Officer until May 2002 and Chairman of the Board until June 2004, and remains a Director of the company. Under his leadership, PDL BioPharma became publicly listed on the NASDAQ stock exchange and brought the first humanized antibody-based pharmaceutical (Zenapax®) from early research to marketing. Previously, Dr. Korn headed a research laboratory and served on the faculty of the Department of Genetics at the Stanford University School of Medicine from March 1981 to December 1986. Before becoming an Assistant Professor at Stanford, Dr. Korn was a Helen Hay Whitney Postdoctoral Fellow at the Carnegie Institution of Washington and a Staff Scientist at the MRC Laboratory of Molecular Biology in Cambridge, England. Dr. Korn received his undergraduate degree from the University of California, Berkeley and his Ph.D. from Stanford University | 